OSPEDALE PEDIATRICO BAMBINO GESU has a total of 18 patent applications. It decreased the IP activity by 75.0%. Its first patent ever was published in 2011. It filed its patents most often in WIPO (World Intellectual Property Organization), Canada and China. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are PREC BIOLOGICS INC, HENLIUS BIOTECH CO LTD and AXON NEUROSCIENCE SE.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 7 | |
#2 | Canada | 3 | |
#3 | China | 3 | |
#4 | Italy | 3 | |
#5 | Australia | 1 | |
#6 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Analysing materials | |
#5 | Measuring microorganism processes | |
#6 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Locatelli Franco | 6 |
#2 | Quintarelli Concetta | 6 |
#3 | De Angelis Biagio | 6 |
#4 | Fierabracci Alessandra | 5 |
#5 | Caruana Ignazio | 5 |
#6 | Muraca Maurizio | 4 |
#7 | Del Chierico Federica | 3 |
#8 | Putignani Lorenza | 3 |
#9 | Moretta Lorenzo | 2 |
#10 | Puccetti Antonio | 2 |
Publication | Filing date | Title |
---|---|---|
WO2021014022A1 | Car-cd123 vector and uses thereof | |
WO2019234779A1 | Use of snp rs17618244 as a predictive marker in nonalcoholic fatty liver disease (nafld) | |
WO2019215772A1 | Short interfering rna targeting variant c1858t of gene ptpn22 | |
IT201800003464A1 | CAR-CD30 T cells for the treatment of CD30 + tumors | |
WO2018024732A1 | Diagnosis and therapy of ankylosing spondylitis | |
US2019136299A1 | Metagenomic method for in vitro diagnosis of gut dysbiosis | |
CN103917275A | Microvesicles isolated from mesenchymal stem cells for use as immunosuppressive agents | |
WO2012101664A1 | Use of at least one p75ntr receptor inhibitor, alone or in association with at least one trka receptor activator, or of at least one trka receptor activator, for the treatment of chronic inflammatory diseases |